Amarin’s Vascepa to become ‘blockbuster,’ analyst says

Amarin (AMRN +1.3%) is up after Aegis analyst Nathan Weinstein says the company’s Vascepa is “well on the way to becoming a blockbuster drug,” which can achieve greater than $1B in annual sales and “peak sales significantly above that.”

In a a “conservative base case” where the drug is approved for secondary prevention along with additional patient qualifications, Vascepa could achieve sales “north of $2B a year” by 2025, Weinstein says in maintaining his Buy rating and $23 price target on the shares.

Also, Jefferies analyst Michael Yee says investors should use AMRN’s recent pullback as a buying opportunity, expecting a strong 2020 launch for Vascepa and noting the company has doubled its salesforce and is launching direct-to-consumer.

https://seekingalpha.com/news/3521887-amarins-vescepa-become-blockbuster-analyst-says-maintaining-buy